Dx & Vx Co., Ltd. (KOSDAQ: A180400)
Health Care · Biotechnology · KR
₩2,745.00
+0.18% today · +6.0% 1Y
Dx & Vx Co., Ltd. (KOSDAQ: A180400) operates in the Biotechnology industry within the Health Care sector. The company is valued at $191.14M.
Over the last twelve months the share price has gained 6.0%, trading between 1.32K and 5.36K.
Tweenvest scores Dx & Vx Co., Ltd. across four factors: quality 37/100, value 60/100. Its strongest factor is value.
A180400 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $191.14M
- Revenue (TTM)
- $18.71M
- P/E
- —
- EPS
- -455.08
- Dividend yield
- —
- Beta (5Y)
- -0.01
- 52-week high
- ₩5,360.00
- 52-week low
- ₩1,319.00
- Avg volume (3M)
- —
- Shares outstanding
- 98.43M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $153.70 | -3.23% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.